Citations

Showing 10 of 108162 citations.

Tirofiban in Suspected Left Ventricular Assist Device Pump Thrombosis
Nei, Scott D. , Wieruszewski, Patrick M. , Orzel, Libby, Ritchie, Brianne M., Stulak, John M., Orzel, Libby A , Wieruszewski, Patrick M

Mayo Clinic

ASAIO Journal | October 14, 2019 | Volume: 66 | Issue: 8 | Pages: 886-889

10.1097/mat.0000000000001083 | PMID 32740348 Get It

Antithrombotic optimization with a glycoprotein IIb/IIIa inhibitor has been used for the treatment of suspected pump thrombosis, but available literature with tirofiban is lacking. This study aims to describe the use of tirofiban for suspected pump thrombosis. This was a single-center cohort study of left ventricular assist device patients who received tirofiban for the treatment of suspected pump thrombosis from January 1, 2016 to July 31, 2017. Tirofiban was initiated at 0.1 μg/kg/min in patients with normal renal function and subsequent dose adjustments for altered renal function or history of bleeding were employed. Success was defined as resolution of lactate dehydrogenase back to patients’ known baseline. Fourteen patients were included for 16 total instances of tirofiban use during the time period. Tirofiban was continued for a median of 5 days (range: 0.3–35 days). Successful treatment was achieved in 12 of the 16 tirofiban uses (75%). Seven bleeding events occurred while on therapy, two major and five minor. This study showed a majority of patients achieved success with tirofiban for suspected pump thrombosis. For patients who are not current candidates for pump exchange or transplant, tirofiban may be considered a therapeutic medical management option.
Improving Recognition, Diagnosis, and Management Of Heparin Induced Thrombocytopenia By Implementing a Computer-Based Clinical Decision Support System
Pruthi, Rajiv K. , Shin, Jennifer S, Dobie, Mark W, Schaefer, Jordan K. , Caraballo, Pedro J.

Mayo Clinic

Blood | October 14, 2019 | Volume: 122 | Issue: 21 | Pages: 2966-2966

10.1182/blood.v122.21.2966.2966 Get It

Abstract Introduction Heparin induced thrombocytopenia (HIT) is often not considered as a potential etiology of thrombocytopenia. The gradual 5 to 14 day decline in platelet count (PC) may not be easily recognized by busy clinicians. The life-threatening complications of HIT are potentially preventable with prompt recognition and management. Implementation of computer-based clinical decision support systems (CDSS) may aid in addressing these issues. Such systems have shown promise in increasing provider recognition, appropriate testing, and management of a variety of conditions. Methods We developed, implemented and evaluated a CDSS designed to identify patients at risk for HIT. The CDSS was integrated into the electronic medical record (Centricity Enterprise, GE) at Mayo Clinic Rochester. The CDSS identified inpatients with recent or active use of heparin medications, who experienced a 50% PC drop. For such patients, the system generated an electronic message alerting their care team of the 50% PC drop and asked them to consider the possibility of HIT. A link to a website with recommendations for the diagnosis and management of HIT was included with the alert. Providers were encouraged to assess for HIT using the 4Ts Score and, if indicated, the anti-heparin/platelet factor 4 (PF4) antibody assay. We performed a retrospective chart review of consecutive patients identified by the system and equal number of randomly generated controls that did not trigger alerts. The accuracy of the algorithm was assessed and errors were analyzed for clinical significance. Patient risk of HIT was evaluated by using the 4Ts Score and the HIT Expert Probability (HEP) Score. Alert effect was classified as: Results Over the study period, 2,785 patients had a total of 37,060 PC (13.31 PC/patient) and the CDSS triggered a total of 124 alerts. About 10% of alerted clinicians reviewed the website with recommendations on the management of HIT. A total of 117 patients generating alerts were compared to 124 controls. Demographics between the two groups were similar. The CDSS had a 95% sensitivity for accurately detecting a 50% platelet drop for inpatients on heparin. The specificity was 74%. The Objective alert effect was found in 21% of the cases (16% of providers changed their management and 5% documented that HIT was felt to be unlikely). The most common actions taken after receiving the alert were obtaining a HIT antibody assay, withholding heparin, consulting a subspecialty service, and/or changing anticoagulants. The Probable alert effect was 14% of the cases. HIT had been considered before the alert was sent in 11% of patients. Alert effect was classified as None for the remaining 54% of patients. Anti-heparin/PF4 testing for HIT was ordered for 25% of the intervention patients compared to 3% of controls. For the intervention group, PF4 was negative for 86% of tested patients, equivocal for 10%, and positive in 3%. All PF4 tests were negative in the control group. 4Ts score was greater than or equal to 4 in 38% of patients and averaged 3.1 (range 7 to 0). HEP score averaged 4 (range 14 to -4). Risk calculations showed a trend to higher risk with therapeutic heparin compared to prophylactic heparin preparations. HIT risk scores were comparable by admitting service and diagnosis. Conclusions Our CDSS successfully identified upwards of 95% of inpatients at risk for HIT. However, approximately 26% of the alerts were false positives. Only a small proportion of clinicians accessed the website with recommendations for the diagnosis and management of HIT but patients with a suspected HIT were managed appropriately. Of the patients triggering a HIT alert, 38% had an intermediate or high clinical probability of HIT based on the 4Ts Score that would be an indication for further testing. This result highlights the success of the CDSS in identifying patients needing further evaluation but also the difficulties of a computer-based CDSS in representing all the important clinical criteria for the diagnosis of HIT. Disclosures: No relevant conflicts of interest to declare.
Thoracic Radiologists’ Versus Computer Scientists’ Perspectives on the Future of Artificial Intelligence in Radiology
Eltorai, Adam E. M. , Bratt, Alex , Guo, H. Henry , Bratt, Alexander K., Bratt, Alex

Mayo Clinic

Journal of Thoracic Imaging | October 14, 2019 | Volume: 35 | Issue: 4 | Pages: 255-259

10.1097/rti.0000000000000453 | PMID 31609778 Get It

Background: There is intense interest and speculation in the application of artificial intelligence (AI) to radiology. The goals of this investigation were (1) to assess thoracic radiologists’ perspectives on the role and expected impact of AI in radiology, and (2) to compare radiologists’ perspectives with those of computer science (CS) experts working in the AI development. Methods: An online survey was developed and distributed to chest radiologists and CS experts at leading academic centers and societies, comparing their expectations of AI’s influence on radiologists’ jobs, job satisfaction, salary, and role in society. Results: A total of 95 radiologists and 45 computer scientists responded. Computer scientists reported having read more scientific journal articles on AI/machine learning in the past year than radiologists (mean [95% confidence interval]=17.1 [9.01-25.2] vs. 7.3 [4.7-9.9], P=0.0047). The impact of AI in radiology is expected to be high, with 57.8% and 73.3% of computer scientists and 31.6% and 61.1% of chest radiologists predicting radiologists’ job will be dramatically different in 5 to 10 years, and 10 to 20 years, respectively. Although very few practitioners in both fields expect radiologists to become obsolete, with 0% expecting radiologist obsolescence in 5 years, in the long run, significantly more computer scientists (15.6%) predict radiologist obsolescence in 10 to 20 years, as compared with 3.2% of radiologists reporting the same (P=0.0128). Overall, both chest radiologists and computer scientists are optimistic about the future of AI in radiology, with large majorities expecting radiologists’ job satisfaction to increase or stay the same (89.5% of radiologists vs. 86.7% of CS experts, P=0.7767), radiologists’ salaries to increase or stay the same (83.2% of radiologists vs. 73.4% of CS experts, P=0.1827), and the role of radiologists in society to improve or stay the same (88.4% vs. 86.7%, P=0.7857). Conclusions: Thoracic radiologists and CS experts are generally positive on the impact of AI in radiology. However, a larger percentage, but still small minority, of computer scientists predict radiologist obsolescence in 10 to 20 years. As the future of AI in radiology unfolds, this study presents a historical timestamp of which group of experts’ perceptions were closer to eventual reality.
Gender and Race As Prognostic Factors In Patients Treated With Rituximab For B-Cell Non-Hodgkin Lymphoma
Aparo, Santiago, Gundabolu, Krishna , Goldfinger, Mendel , Barta, Stefan K

Mayo Clinic

Blood | October 14, 2019 | Volume: 122 | Issue: 21 | Pages: 3053-3053

10.1182/blood.v122.21.3053.3053 Get It

Abstract Introduction The International Prognostic Index (IPI) and the age-adjusted IPI (aaIPI) are the most commonly used tools to predict outcomes in patients with Non-Hodgkin Lymphoma (NHL). The IPI does not take into account sex or race. In the pre-rituximab era, sex was found to be a strong predictor of poor prognosis in low-grade lymphomas. While there is emerging evidence that female sex is associated with better survival in patients with diffuse large B-cell lymphoma (DLBCL) treated with R-CHOP, much less is known about the prognostic impact of race. We retrospectively assessed the impact of sex and race on overall survival in patients with indolent and aggressive NHL treated at any stage with rituximab at our institution. Methods We retrospectively identified all patients >/=18 years who were diagnosed with B-cell NHL (except SLL/CLL and Burkitt lymphoma) between 1/1/2000 and 12/31/2010 and received rituximab at any stage as part of their therapy at the Montefiore Medical Center. We collected data on histology, age (<60 vs. >/=60), date of diagnosis, date and status at last follow-up, and stage from the MECCC Cancer registry, and we obtained data on the Charlson Comorbidity Index (CCI) from Clinical Looking Glass® (CLG), an interactive software application developed at Montefiore Medical Center which integrates clinical and administrative datasets. The histological subtypes DLBCL and grade 3 follicular lymphoma (FL) were classified as “high-grade lymphoma” (HGL), while other types of lymphoma were termed “low-grade lymphoma” (LGL; these included marginal zone lymphoma, mantle cell lymphoma, grade 1 & 2 FL, and malignant lymphoma NOS). Self-reported race was classified as White, Black, Hispanic or “Other”. Only <2% of the patients were of “Other” racial background and therefore excluded from this analysis. The primary outcome was overall survival (OS) calculated as time from diagnosis to time of death. We used the Kaplan-Meier (KM) method to describe OS for race and sex and the log-rank test to test for significance (p<0.05). We used a Cox proportional hazard (CPH) model to assess the association of variables with OS. Except for age, race and sex, variables that were not significantly associated with OS (i.e. p-value>0.10 in the multivariate model) were excluded from the final model (backward elimination). Results 353 patients were included in the analysis. Median follow-up for all patients was 37.3 months (range 0.03-202.40). Baseline characteristics between male and females were similar with the exception of age at diagnosis and histology (see Table 1). On univariate analysis there was no OS difference between male and female patients (p=0.13), while race was associated with significant differences in OS (p=0.04; see Fig. 1). In the multivariate model, only stage >/=3 was associated with worse survival (Hazard Ratio [HR] 2.78, 95% CI 1.62-4.77; p<0.0001), but there was no significant association with OS for type of lymphoma (HGL vs. LGL) or the CCI (low vs. high score) and these 2 variables were therefore eliminated from the final multivariate model. In the final multivariate model, female sex was associated with a 37% reduction in the risk of death (HR 0.63; 95%CI 0.40-0.98; p=0.04), while race was no longer associated with OS (Hispanic vs. White: HR 0.76, 95%CI 0.41-1.40, p=0.38; Black vs. White: HR 0.66, 95%CI 0.40-1.10; p=0.11; Black vs. Hispanic: HR 1.15; 95% CI 0.63-2.08, p=0.65). Conclusions Female patients treated at any stage with rituximab for high-grade and low-grade B-cell NHL at our institution experienced longer OS. However, we observed no racial disparity in survival in our analysis. Disclosures: No relevant conflicts of interest to declare.
Comparison of Magnetic Resonance Imaging and Transrectal Ultrasound Informed Prostate Biopsy for Prostate Cancer Diagnosis in Biopsy Naïve Men: A Systematic Review and Meta-Analysis
Chandrasekar, Thenappan , Klotz, Laurence , Emberton, Mark , Haider, Masoom A. , Taneja, Samir S. , Fleshner, Neil , Finelli, Antonio , Perlis, Nathan , Tyson, Mark D. , Klaassen, Zachary , Arora, Karan, Goldberg, Hanan , Ahmad, Ardalan E. , Arora, Karan , Wallis, Christopher J D

Mayo Clinic

Journal of Urology | October 14, 2019 | Volume: 203 | Issue: 6 | Pages: 1085-1093

10.1097/ju.0000000000000595 | PMID 31609177 Get It

Vasoactive Intestinal Peptide–Secreting Tumors
Siddappa, Pradeep K. , Vege, Santhi Swaroop

Mayo Clinic

Pancreas | October 14, 2019 | Volume: 48 | Issue: 9 | Pages: 1119-1125

10.1097/mpa.0000000000001402 | PMID 31609932 Get It

Abstract Vasoactive intestinal peptide–secreting tumors (VIPomas) are a group of rare neuroendocrine tumors, which cause a typical syndrome of watery diarrhea. Most of these tumors are found in the pancreas and are usually detected at a later stage. Although curative resection is not possible in most of these tumors, both symptom and tumor control can be achieved by a multidimensional approach, to enable a long survival of most patients. There are no clear-cut guidelines for the management of VIPomas because of the rarity of this neoplasm and lack of prospective data. In this review, we discuss the available evidence on the clinical features and management of these rare tumors.
Platelet Storage Pool Deficiency: Establishment Of Reference Ranges For Platelet Dense Granule Count By Transmission Electron Microscopy
Uhl, Cindy B., Barness, Ryan L., Olson, Mary C. , Gossman, Susan C., Erdoğan, Sibel , Gamb, Scott I., Charlesworth, Jon E. , Lingineni, Ravi K., Bryant, Sandra C. , Miller, Randall S., Salisbury, Jeffery L., Nichols, William L., White, James G. , Olson, Mary C., Erdogan, Sibel, Chen, Dong

Mayo Clinic

Blood | October 14, 2019 | Volume: 122 | Issue: 21 | Pages: 3549-3549

10.1182/blood.v122.21.3549.3549 Get It

Abstract Background Platelet dense granule (DG) deficiencies, including Hermansky-Pudlak syndrome, are relatively common and frequently under-diagnosed hereditary platelet hypofunctional disorders. Among various laboratory tests, platelet whole mount (WM) transmission electron microscopy (TEM) is considered the gold standard method for diagnosing DG deficiencies. Nevertheless, platelet DG TEM testing is still largely a research tool and has not been thoroughly validated and standardized as a clinical test. Furthermore, reference ranges (RR) of DG count/platelet (DGC) have not been adequately established. Aim Our goals were to validate and standardize platelet WM TEM testing and establish reference ranges for platelet DGC. Methods Based on previously established methods (Blood, 33:598-606), we first optimized and standardized various pre-analytical, analytical and post-analytical procedures including sample matrix, sample stability, platelet-rich plasma (PRP) preparation, platelet mounting procedure and DG counting criteria. Then whole blood samples in ACD-B tubes were collected from a total of 128 healthy donors (64 males and 64 females). Platelet DGC, percentage of platelets without any DG (empty platelets), platelet count (PC), mean platelet volume (MPV) and immature platelet fraction (IPF) were measured. In addition, platelet aggregometry analyses were performed on citrated PRP samples from the same donors. Standard statistical analyses were employed in this study. Results DGC and platelet ultra-structure were stable when whole blood samples were stored at room temperature (RT) for up to 4 days. Reproducible DGC and adequate preservation of platelet ultrastructure depended on an optimized mounting method. The DG counting criteria were developed based on previous publications and guidance from Dr. James G. White. Using the same WM TEM images and DG counting criteria, agreements among different technologists (n=5) improved from 60% to 95%. Finally, DGC reference range study using 128 healthy donor samples (age range 18, 72 years) and scoring 100-200 platelets from each donor showed that the DGC distribution of each donor sample was left-skewed with a median of 15% of empty platelets (range: 3, 40). The median DGC was 2.6 with a range of 1.0—5.1. Reference ranges established at the lower 95th percentile for DGC empty platelets is ≤ 31% (95% CI 28, 34) and for the mid-95th percentiles of DGCs between 1.5 and 4.0. DGCs were weakly associated with MPV and IPF (ρ between 0.22 and 0.28); and inversely associated with the percentage of empty platelets (ρ between -0.26 and -0.25). DGC showed no significant association with PC, platelet maximum aggregation or primary slope of aggregation, nor age or gender. Conclusion We validated platelet WM TEM procedures and for the first time established an adult reference range for platelet DGC. The results of association analyses implied that immature platelets may have slightly more DGs. Disclosures: No relevant conflicts of interest to declare.
Clinical and Quality of Life Predictors of Failure to Achieve Event Free Survival at 24 Months in Patients Aged 70 Years and Older with Diffuse Large B-Cell Lymphoma
Thanarajasingam, Gita , Yost, Kathleen J. , Thompson, Carrie A. , Reagan, Patrick Michael , Baran, Andrea , Maurer, Matthew J. , Feldman, Andrew L. , Habermann, Thomas M. , Slager, Susan L. , Link, Brian K. , Cerhan, James R.

Mayo Clinic

Blood | October 14, 2019 | Volume: 132 | Issue: Supplement 1 | Pages: 3579-3579

10.1182/blood-2018-99-118356 Get It

Abstract Background Age has long been recognized as a poor prognostic factor in diffuse large B-cell lymphoma (DLBCL) and more recently, a lower baseline quality of life (QOL) in patients with aggressive lymphomas has been associated with an inferior overall survival (OS) (Thompson et al, 2018). Older patients with DLBCL are a heterogeneous population and commonly have comorbid conditions. A concerted effort to identify prognostic factors specific to this population is needed, including QOL. Event free survival at 24 months (EFS24) is a well validated endpoint in DLBCL (Maurer et al, 2014) and is clinically relevant in older patients. We hypothesized that baseline clinical factors and QOL would be associated with EFS24 this patient group. Methods Newly diagnosed lymphoma patients were prospectively enrolled within 9 months of diagnosis into the University of Iowa/Mayo Clinic Lymphoma SPORE Molecular Epidemiology Resource (MER). Patients ≥70 years of age with DLBCL were utilized in this study. All pathology was reviewed by a lymphoma hematopathologist. Clinical variables were abstracted from the medical record. QOL was assessed at enrollment using a single item Linear Analogue Self-Assessment (LASA) and the 27-item Functional Assessment of Cancer Treatment-General questionnaire (FACT-G), which includes physical, social, emotional, and functional well-being domains. QOL scores were converted to a 0-100 scale to facilitate modeling. QOL was analyzed in patients who completed 80% of the FACT-G questions. Characteristics of the study population were compared using the Wilcoxon rank sum test. Odds ratios (ORs) and 95% confidence intervals (CI) were used to estimate the associations of clinical and continuous QOL variables with failure to achieve EFS24 using logistic regression models, with a stepwise approach to identify parsimonious multivariate models. Results A total of 389 patients ≥70 years were identified with DLBCL in the MER from 2002-2015; patient characteristics are described in the Table. In the entire study population, univariate predictors of EFS24 failure included age (OR per 10 years=1.85, 95% CI: 1.26-2.71), ECOG PS ≥2 (OR=4.78, 95% CI: 2.92-7.83), elevated LDH (OR=3.59, 95% CI: 2.27-5.65), stage III-IV (OR=1.94, 1.25-3.02), bulky disease (OR=2.86, 95% CI: 1.43-5.72), international prognostic index (OR=8.71 for IPI 5 vs IPI 0, 95% CI: 3.04-24.9), and receipt of an anthracycline (OR=0.25, 95% CI: 0.12-0.51), while none of the other variables in the Table, including the QOL variables, were statistically significant. In a stepwise multivariate analysis, only ECOG PS ≥2 (OR= 3.56, 95% CI: 2.09-6.06) and elevated LDH (OR=2.86, 95% CI: 1.78-4.60) remained significant predictors of EFS24 failure. QOL data were available on 220 patients, with 120 completing QOL questionnaires prior to receipt of chemotherapy. Compared to participants who completed their FACT-G before the initiation of chemotherapy, the median FACT-G physical (85.7 v. 71.4, p=0.005) and functional (71.4 vs 57.1, p=0.008) scores were lower in participants completing FACT-G after initiation of therapy, were higher on FACT-G emotional (79.2 vs 83.3, p=0.03), and showed no differences on FACT-G social (89.3 vs 91.7, p=0.60) or FACT-G total score (78.2 vs 74.1, p=0.17). Given these differences, we restricted the QOL analysis to those with pre-treatment data. In univariate analysis, the LASA score (OR= 0.98, 95% CI: 0.84-1.14), the FACT-G total (OR=0.99, 95% CI: 0.96-1.01), physical (OR=0.98, 95% CI: 0.97-1.00), social (OR=1.00, 95% CI: 0.98-1.03), emotional (OR= 1.00, 95% CI: 0.98-1.02), and functional (OR=0.99, 95% CI: 0.98-1.01) scores were not associated with EFS24 failure. In a stepwise multivariate analysis of clinical variables in patients with pretreatment QOL scores, only ECOG PS ≥2 (OR=3.56, 95% CI: 1.30-9.72) and female sex (OR=0.37, 95% CI: 0.16-0.85) were associated with failure to achieve EFS24. Conclusions In patients aged 70 years and older, ECOG PS and LDH were the strongest independent predictors of failure to achieve EFS24. As expected, physical and functional scores were lower in patients who completed their QOL after initiation of treatment. Restricting the analysis to patients with pre-treatment data, QOL was not associated with failure to achieve EFS24. Additional studies are needed to identify the most robust clinical predictors of EFS24, while QOL does not appear to be an important predictor of EFS24. Disclosures Reagan: Seattle Genetics: Research Funding. Maurer:Morphosys: Research Funding; Celgene: Research Funding; Nanostring: Research Funding. Cerhan:Celgene: Research Funding; Nanostring: Research Funding; Jannsen: Other: Scientific Advisory Board.
Macrophage Transplantation Fails to Improve Repair of Critical-Sized Calvarial Defects
Borrelli, Mimi R. , Hu, Michael S. , Hong, Wan Xing , Oliver, Jeremie D. , Longaker, Michael T. , Lorenz, H. Peter , Oliver, Jeremie D , Longaker, Michael T , Duscher, Dominik

Mayo Clinic

Journal of Craniofacial Surgery | October 14, 2019 | Volume: 30 | Issue: 8 | Pages: 2640-2645

10.1097/scs.0000000000005797 | PMID 31609958 Get It

Introduction: Over 500,000 bone grafting procedures are performed every year in the United States for neoplastic and traumatic lesions of the craniofacial skeleton, costing $585 million in medical care. Current bone grafting procedures are limited, and full-thickness critical-sized defects (CSDs) of the adult human skull thus pose a substantial reconstructive challenge for the craniofacial surgeon. Cell-based strategies have been shown to safely and efficaciously accelerate the rate of bone formation in CSDs in animals. The authors recently demonstrated that supraphysiological transplantation of macrophages seeded in pullalan–collagen composite hydrogels significantly accelerated wound healing in wild type and diabetic mice, an effect mediated in part by enhancing angiogenesis. In this study, the authors investigated the bone healing effects of macrophage transplantation into CSDs of mice. Methods: CD1 athymic nude mice (60 days of age) were anesthetized, and unilateral full-thickness critical-sized (4 mm in diameter) cranial defects were created in the right parietal bone, avoiding cranial sutures. Macrophages were isolated from FVB-L2G mice and seeded onto hydroxyapatite-poly (lactic-co-glycolic acid) (HA-PLGA) scaffolds (1.0 × 106 cells per CSD). Scaffolds were incubated for 24 hours before they were placed into the CSDs. Macrophage survival was assessed using three-dimensional in vivo imaging system (3D IVIS)/micro-CT. Micro-CT at 0, 2, 4, 6, and 8 weeks was performed to evaluate gross bone formation, which was quantified using Adobe Photoshop. Microscopic evidence of bone regeneration was assessed at 8 weeks by histology. Bone formation and macrophage survival were compared at each time point using independent samples t tests. Results: Transplantation of macrophages at supraphysiological concentration had no effect on the formation of bones in CSDs as assessed by either micro-CT data at any time point analyzed (all P > 0.05). These results were corroborated by histology. 3D IVIS/micro-CT demonstrated survival of macrophages through 8 weeks. Conclusion: Supraphysiologic delivery of macrophages to CSDs of mice had no effect on bone formation despite survival of transplanted macrophages through to 8 weeks posttransplantation. Further research into the physiological effects of macrophages on bone regeneration is needed to assess whether recapitulation of these conditions in macrophage-based therapy can promote the healing of large cranial defects.
Cranial Fossa Volume in Differing Subtypes of Apert Syndrome
Lu, Xiaona , Forte, Antonio J. , Wilson, Alexander T. , Alperovich, Michael , Steinbacher, Derek M., Alonso, Nivaldo , Persing, John A. , Forte, Antonio Jorge

Mayo Clinic

Journal of Craniofacial Surgery | October 14, 2019 | Volume: 30 | Issue: 8 | Pages: 2345-2349

10.1097/scs.0000000000005785 | PMID 31609946 Get It

Background: Based on an established classification system of Apert syndrome subtypes, detailed regional morphology and volume analysis may be useful to provide additional clarification to individual Apert cranial structure characteristics, and treatment planning. Methods: Computed tomography scans of 32 unoperated Apert syndrome and 50 controls were included and subgrouped as: type I, bilateral coronal synostosis; type II, pansynostosis; type III, perpendicular combination synostosis. Three-dimensional analysis of craniometric points was used to define structural components using Materialise Mimics and 3-Matics software. Results: Occipitofrontal circumference of all subtypes of Apert syndrome patients is normal. Intracranial volumes of types I and II were normal, but type III was 20% greater than controls. Middle cranial fossa volume was increased in all 3 types, with the greatest increase in type II (86%). Type II developed a 69% increase in anterior cranial fossa volume, whereas type III had 39% greater posterior cranial fossa volume. Increased cranial fossa depth contributed most to above increased volume. The anteroposterior lengths of middle and posterior cranial fossae were reduced in type I (15% and 17%, respectively). However, only the anterior cranial fossa was significantly shortened in type III. Conclusions: Occipitofrontal circumference and overall intracranial volume is not always consistent in individual subunits of Apert syndrome. Detailed and segmental anterior, middle, and posterior cranial fossae volumes and morphology should be analyzed to see what impact this may have related to surgical planning.